<DOC>
	<DOC>NCT00166842</DOC>
	<brief_summary>The purpose of this study is to understand the pharmacokinetics of sirolimus tablets in different regimens in newly renal transplant patients, and the effect of dosage form conversion on the concentration of sirolimus in stable renal transplant patients. So that we can design a better tacrolimus or cyclosporine/sirolimus/steroid dose regimen for Taiwanese.</brief_summary>
	<brief_title>Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets</brief_title>
	<detailed_description>Sirolimus tablets will be available more than one year after the launch of sirolimus solution. Most patients on sirolimus solution will use sirolimus tablet instead. The purpose of this study is to understand the pharmacokinetics of sirolimus tablets in different regimens in newly renal transplant patients, and the effect of dosage form conversion on the concentration of sirolimus in stable renal transplant patients. So that we can design a better tacrolimus or cyclosporine/sirolimus/steroid dose regimen for Taiwanese.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>ages of 18 and 65, renal transplant patients pregnancy, tuberculosis, hepatitis B or C carrier status, human immunodeficiency virusÔºçpositive status, retransplantation or multiorgan transplantation, or history of rheumatoid arthritis before transplantation</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>